# OnCo record paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026" ;
  schema:name "Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02"@en ;
  schema:description "In the tumour-agnostic trial that led to the HER2 IHC 3+ approval, trastuzumab deruxtecan shrank about a quarter of 41 pretreated biliary cancers overall and more than half of those with the strongest HER2 stain, while pancreatic tumours barely responded."@en ;
  schema:url <https://onco.cc/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.esmoop.2026.108344>, <https://pubmed.ncbi.nlm.nih.gov/42531802/>, <https://clinicaltrials.gov/study/NCT04482309> ;
  schema:sameAs <https://doi.org/10.1016/j.esmoop.2026.108344> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Oh DY, Lugowska I, Stroyakovskiy D, et al." ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/biliary-tract-cancer/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/> ;
  onco:trials <https://onco.cc/trials/destiny-pantumor02/> ;
  onco:people <https://onco.cc/people/oh-do-youn/> .